A novel Edwardsiella ictaluri E-ict-VL33 strain, a vaccine derived from the novel Edwardsiella ictaluri E-ict-VL33 strain, especially in immersion form and oral form, and a method for protecting fishes from the infection of Edwardsiella ictaluri , especially catfish, the method including a primary immersion immunization using immersion vaccine, and after an appropriate period, boosting by oral vaccination, resulting in a strong and long-lasting immunity for fishes.
1. A novel purified and isolated Edwardsiella ictaluri E-ict-VL33 strain which is ATCC deposit number PTA-10711.
2. A vaccine composition comprising the Edwardsiella ictaluri E-ict-VL33 strain as recited in claim 1 , which is prepared from the inactivation of Edwardsiella ictaluri E-ict-VL33 strain by an inactivation agent.
3. The vaccine composition as recited in claim 2 , wherein said inactivation agent is formaldehyde or binary ethyleneimine (BEI).
4. The vaccine composition as recited in claim 2 , further comprising a pharmaceutically acceptable vehicle.
5. The vaccine composition as recited in claim 4 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of at least one of solvent, emulsifier, suspending agent, decomposer, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, surfactant, and adjuvant.
6. The vaccine composition as recited in claim 5 , wherein the pharmaceutically acceptable vehicle is an adjuvant is selected from the group consisting of at least one of oleaginous adjuvant, aqueous adjuvant, two-phase oleaginous adjuvant, and biological adjuvant.
7. The vaccine composition as recited in claim 6 , wherein the adjuvant is an oleaginous adjuvant, selected from the group consisting of at least one of mineral oil, plant oil, animal oil, Freund's Complete Adjuvant and Freund's Incomplete Adjuvant.
8. The vaccine composition as recited in claim 6 , wherein the adjuvant is an aqueous adjuvant, wherein the aqueous adjuvant is aluminium hydroxide.
9. The vaccine composition as recited in claim 6 , wherein the adjuvant is two-phase oleaginous adjuvant wherein the two-phase oleaginous adjuvant comprises a surfactant and an oleaginous substance.
10. The vaccine composition as recited in claim 9 , wherein the surfactant is selected from the group consisting of: at least one of sorbitol fatty acid ester, the concentrate of sorbitol fatty acid ester and ethylene oxide or propylene oxide, mannitol fatty acid ester, the concentrate of mannitol fatty acid ester and ethylene oxide or propylene oxide, modified mannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; anhydromannitol fatty acid ester, modified anhydromannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; saccharose fatty acid ester, the concentrate of saccharose fatty acid ester and ethylene oxide or propylene oxide, glycerol fatty acid ester, the concentrate of glycerol fatty acid ester and ethylene oxide or propylene oxide, the concentrate of fatty acid and ethylene oxide or propylene oxide, the concentrate of fatty alcohol and ethylene oxide or propylene oxide, and glycerophospholipid.
11. The vaccine composition as recited in claim 9 , wherein the oleaginous substance is selected from the group consisting of: at least one of mineral oil, plant oil and animal oil.
12. The vaccine composition as recited in claim 6 , wherein the adjuvant is biological adjuvant wherein the biological adjuvant is selected from the group consisting of at least one of oligonucleotide and toxoid.